Sponsor and CRO Share Perspective on Mitigating COVID-19 Risks in a Complex Pain Program in Free Webinar
Sponsor and CRO Share Perspective on Mitigating COVID-19 Risks in a Complex Pain Program in Free Webinar
WHAT: UNITY Biotechnology partnered with Rho to execute a complex and fast-moving Osteoarthritis program with three concurrent clinical trials and database locks, scheduled during the height of the COVID-19 pandemic.
UNITY and Rho are offering a free webinar, “Mitigating COVID-19 Risks in a Complex Pain Program – a Sponsor and CRO Perspective”, on Wednesday, May 19, from 1-2 p.m. EST, to highlight the creative solutions they implemented to keep the trial on track, as well as how they worked together to pivot quickly and meet critical study timelines amid the pandemic.
Topics in this webinar will include:
ü Challenges this team overcame during program execution
ü Real-world solutions to keep your program on-track during COVID-19
ü Insights for productive collaboration between Sponsors and CROs
WHO: Akbar Khan, VP of Clinical Operations, UNITY Biotechnology
Nicholas Poulson, Senior Project Manager, Rho
Fran Sawyer, Clinical Team Lead, Rho
WHEN: Wednesday, May 19, 2021, 1-2 p.m. EST
WHERE: Register to attend this free webinar at this link.
DETAILS: For media inquiries, please contact Kelly Maicon at Largemouth Communications, 919-459-6450, kmaicon@largemouthpr.com.
ABOUT: Rho, a privately-held, contract research organization (CRO) located in Research Triangle Park, NC, provides a full range of clinical research services across the entire drug development process. For over 35 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com and follow us on Facebook, LinkedIn and Twitter.